CO2020004801A2 - Uso de suplementos de aminoácidos para mejorar la síntesis de proteínas musculares - Google Patents

Uso de suplementos de aminoácidos para mejorar la síntesis de proteínas musculares

Info

Publication number
CO2020004801A2
CO2020004801A2 CONC2020/0004801A CO2020004801A CO2020004801A2 CO 2020004801 A2 CO2020004801 A2 CO 2020004801A2 CO 2020004801 A CO2020004801 A CO 2020004801A CO 2020004801 A2 CO2020004801 A2 CO 2020004801A2
Authority
CO
Colombia
Prior art keywords
protein synthesis
amino acid
muscle protein
muscle
improve muscle
Prior art date
Application number
CONC2020/0004801A
Other languages
English (en)
Inventor
Robert R Wolfe
Arny Ferrando
Original Assignee
Bioventures Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioventures Llc filed Critical Bioventures Llc
Publication of CO2020004801A2 publication Critical patent/CO2020004801A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/0624—Histidine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/0626—Isoleucine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/0628—Leucine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/063—Lysine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/0632—Methionine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/0638—Phenylalanine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/0648—Threonine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/065—Tryptophan
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/0654—Valine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

RESUMEN La presente invención abarca una composición de aminoácidos para estimular síntesis de proteínas musculares. Además, la presente descripción hace referencia, en términos generales, al uso de una composición de aminoácidos anabólicos para la estimulación de la síntesis de proteínas musculares. En particular, se describen composiciones y métodos para utilizarlos para la prevención y/o tratamiento de una pérdida de cualquiera de masa muscular, fuerza muscular, función muscular y función física, o cualquier combinación de estas, en un mamífero, especialmente un mamífero adulto. También se proporcionan kits que comprenden una composición para la estimulación de la síntesis de proteínas musculares y, en determinadas modalidades, instrucciones para su administración.
CONC2020/0004801A 2017-11-02 2020-04-17 Uso de suplementos de aminoácidos para mejorar la síntesis de proteínas musculares CO2020004801A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762580861P 2017-11-02 2017-11-02
PCT/US2018/058937 WO2019090061A1 (en) 2017-11-02 2018-11-02 Use of amino acid supplementation for improved muscle protein synthesis

Publications (1)

Publication Number Publication Date
CO2020004801A2 true CO2020004801A2 (es) 2020-05-05

Family

ID=66332726

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0004801A CO2020004801A2 (es) 2017-11-02 2020-04-17 Uso de suplementos de aminoácidos para mejorar la síntesis de proteínas musculares

Country Status (11)

Country Link
US (1) US11273138B2 (es)
EP (1) EP3703516A4 (es)
JP (3) JP7529566B2 (es)
KR (2) KR102775380B1 (es)
CN (2) CN118178404A (es)
CA (1) CA3079518C (es)
CO (1) CO2020004801A2 (es)
MX (1) MX2020004397A (es)
MY (1) MY209392A (es)
SG (1) SG11202003370VA (es)
WO (1) WO2019090061A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3703516A4 (en) * 2017-11-02 2021-08-18 BioVentures, LLC USE OF AMINO ACID SUPPLEMENTATION FOR IMPROVED MUSCLE PROTEIN SYNTHESIS
CN113924089A (zh) * 2019-06-07 2022-01-11 雀巢产品有限公司 使用一种或多种自噬诱发氨基酸来增强一种或多种合成代谢氨基酸的肌肉骨骼效应的组合物和方法
CA3143450A1 (en) * 2019-06-20 2020-12-24 Societe Des Produits Nestle S.A. Compositions and methods to potentiate musculoskeletal effect of one or more anabolic amino acids
WO2021198400A1 (en) * 2020-04-01 2021-10-07 Société des Produits Nestlé S.A. Compositions containing amino acids and methods of using such compositions for treating sarcopenia
EP4701445A1 (en) * 2023-04-28 2026-03-04 Orivian Inc. A dietary supplement combination and use thereof for improving muscle performance

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851226A (en) 1987-11-16 1989-07-25 Mcneil Consumer Products Company Chewable medicament tablet containing means for taste masking
DE3916903A1 (de) * 1989-05-24 1991-02-28 Leopold Pharma Gmbh Waessrige zusammensetzung fuer die parenterale ernaehrung
AU7148791A (en) * 1989-12-29 1991-07-24 Mcgaw, Inc. The use of arginine as an immunostimulator
US5075114A (en) 1990-05-23 1991-12-24 Mcneil-Ppc, Inc. Taste masking and sustained release coatings for pharmaceuticals
CA2128820A1 (en) 1993-07-27 1995-01-28 Walter G. Gowan, Jr. Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof
US5817329A (en) 1997-02-28 1998-10-06 Gardiner; Paul T. Nutritional supplement for increased muscle size and strength for body builders
EP1274858A1 (de) 2000-04-17 2003-01-15 Befa Handelsgesellschaft mbH Verfahren zur bestimmung der konzentration von carnitin in flüssigen substanzen
US20040087490A1 (en) 2002-09-20 2004-05-06 Troup John P. Nutritional compositions
US7288570B2 (en) 2002-12-20 2007-10-30 Nutricia N.V. Stimulation of in vivo production of proteins
JPWO2005104873A1 (ja) * 2004-04-28 2008-03-13 大塚製薬株式会社 アミノ酸含有食品
WO2006105112A2 (en) * 2005-03-29 2006-10-05 Ajinomoto Co., Inc. Amino acid-containing composition for preventing or remedying in the skeletal muscle of aged people
JPWO2007023999A1 (ja) * 2005-08-24 2009-03-05 味の素株式会社 アミノ酸含有酸性飲料及びその製造方法
US20090297689A1 (en) 2006-06-26 2009-12-03 Luppo Edens Peptidylarginine deiminase and uses thereof in the production of citrullinated proteins and peptides
US20080268038A1 (en) 2007-04-26 2008-10-30 Wolfe Robert R Compositions and Approaches for Increasing Diet Induced Thermogenesis, Inducing Weight Loss and Maintaining Muscle Mass and Strength
US7790688B2 (en) 2008-01-11 2010-09-07 Healthspan Solutions, Llc Compositions and methods for increasing muscle mass, strength, and functional performance in the elderly
CN102803485A (zh) 2009-06-24 2012-11-28 日本烟草产业株式会社 修饰型生物素结合蛋白
WO2011078654A1 (en) * 2009-12-24 2011-06-30 N.V. Nutricia Low-caloric high-protein nutritional composition for the stimulation of muscle protein synthesis
WO2012005568A1 (en) 2010-07-07 2012-01-12 N.V. Nutricia Nutritional composition for the stimulation of muscle protein synthesis
US20130203701A1 (en) 2010-09-17 2013-08-08 Maine Natural Health, Inc. Compositions containing omega-3 oil and uses thereof
WO2013075095A1 (en) * 2011-11-18 2013-05-23 The Board Of Trustees Of The University Of Arkansas Use of amino acid supplementation for improved muscle recovery
US9597367B2 (en) 2013-04-19 2017-03-21 Bioventures, Llc Methods for improving muscle and heart function
WO2014191856A1 (en) * 2013-05-31 2014-12-04 Nestec S.A. Methods for enhancement of muscle protein synthesis
RU2016110800A (ru) 2013-09-25 2017-10-30 Пронутриа Биосайенсис, Инк. Составы и композиции для поддержания и увеличения мышечной массы, силы и результативности, и способы их производства и использования
EP3389385A1 (en) * 2015-12-18 2018-10-24 Lonza Inc. Method and composition for increasing muscle protein synthesis and/or functional strength in mammals as well as method of producing a composition
EP3703516A4 (en) * 2017-11-02 2021-08-18 BioVentures, LLC USE OF AMINO ACID SUPPLEMENTATION FOR IMPROVED MUSCLE PROTEIN SYNTHESIS

Also Published As

Publication number Publication date
CN111295102A (zh) 2020-06-16
KR20200083977A (ko) 2020-07-09
JP2025090715A (ja) 2025-06-17
KR102775380B1 (ko) 2025-03-04
EP3703516A4 (en) 2021-08-18
KR20250036934A (ko) 2025-03-14
CN118178404A (zh) 2024-06-14
BR112020007447A2 (pt) 2020-12-08
RU2020117917A3 (es) 2022-02-04
SG11202003370VA (en) 2020-05-28
MY209392A (en) 2025-07-07
RU2020117917A (ru) 2021-12-02
EP3703516A1 (en) 2020-09-09
MX2020004397A (es) 2020-08-06
US20200253908A1 (en) 2020-08-13
JP7529566B2 (ja) 2024-08-06
WO2019090061A1 (en) 2019-05-09
CA3079518A1 (en) 2019-05-09
JP2021501746A (ja) 2021-01-21
CA3079518C (en) 2025-05-13
JP7716119B2 (ja) 2025-07-31
JP2023154042A (ja) 2023-10-18
US11273138B2 (en) 2022-03-15

Similar Documents

Publication Publication Date Title
CO2020004801A2 (es) Uso de suplementos de aminoácidos para mejorar la síntesis de proteínas musculares
BR112019000598A2 (pt) rna para terapia de câncer
CO2019013707A2 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson
ECSP19043725A (es) Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares
BR112017018368A2 (pt) composições contendo rna para o tratamento de doenças tumorais
MX2025008493A (es) Agentes de union a fibroblastos y uso de estos
BR112017017949A2 (pt) regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna
MX2018002990A (es) Uso de la akkermansia pasteurizada para tratar trastornos metabolicos.
AR080685A1 (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
BR112015022514A2 (pt) composições que compreendem selênio e uso das mesmas para o tratamento e prevenção de doença ou condições associadas à disfunção mitocondrial
CR9994A (es) Vacuna terapéutica
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
BR112012018951C8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
BR112015026247A8 (pt) composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit
MX386216B (es) Uso de estimuladores de guanilato ciclasa soluble (sgc) para el tratamiento de esteatohepatitis no alcohólica (nash).
MX2016015668A (es) Procedimiento de disminucion de la inmunogenicidad de proteinas y peptidos.
MX2021004566A (es) Compuestos terapeuticos.
BR112012015202A2 (pt) "iota - e/ou kappa-carrgenado junto com um inibidor da neuraminidase, método para o tratamento profilático ou terapêutico de um sintoma, condição ou doença, composição farmacêutica,e, kit de partes".
PY2188555A (es) Composiciones y métodos para la prevención y/o tratamiento de la covid-19
BR112017016497A2 (pt) composições e métodos para metabolismo muscular melhorado
MX2021015501A (es) Anticuerpos y metodos de uso.
BR112019001082A2 (pt) gel intestinal de levodopa e carbidopa e métodos de uso
PY2285025A (es) Composiciones y métodos para la prevención y/o tratamiento de la covid-19
MX2020004214A (es) Sales de (r)-9-(2,5-difluorofenetil)-4-etil-2-metil-1-oxa-4,9-diaz aspiro[5.5]undecan-3-ona.
EA201891739A1 (ru) ПРИМЕНЕНИЕ СТИМУЛЯТОРОВ sGC ДЛЯ ЛЕЧЕНИЯ НЕАЛКОГОЛЬНОГО СТЕАТОГЕПАТИТА (NASH)